101 results about "Reticulocyte" patented technology

The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal α-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula

—CO—(CH₂)_x—(OCH₂CH₂)_m—OR

wherein the —CO of the poly(ethylene glycol) group forms an amide bond with said N-terminal α-amino group; and wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.

The invention provides a protein synthesis system for in-vitro protein synthesis, a kit and a preparation method for a protein through in-vitro synthesis. Specifically, the in-vitro cell-free expression system provided by the invention is capable of extremely efficiently synthesizing proteins and synthesizing complex proteins. Moreover, due to the in-vitro cell-free expression system disclosed bythe invention, the relative light unit value of the activity of the synthesized luciferase is higher than that of the conventional commercial system (such as a rabbit reticulocyte in-vitro expressionsystem) by at least one order of magnitude (more than or equal to 10 times or higher).

This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.

A method whereby one or more fluorescent dyes are used to bind and stain nucleic acids in certain blood cells, such as, for example, white blood cells, nucleated red blood cells, and reticulocytes, and to induce fluorescent emissions upon excitation of photons from a given source of light, such as, for example, a laser, at an appropriate wavelength. More particularly, this invention provides a method whereby a fluorescent trigger is used in a data collection step for collecting events that emit strong fluorescence, in order to separate white blood cells and nucleated red blood cells from red blood cells and platelets without the need for using a lysing agent.

A method of making a reference control containing a nucleated red blood cell component includes providing a blood cell containing a nucleus; treating the blood cell with a treatment solution to alter a nucleus property from a natural value to a target value suitable for simulating nucleated red blood cells on a blood analyzer; and suspending treated blood cell in a suspension medium to form a reference control. The method also includes integrating the nucleated red blood cell component with white blood cell, red blood cell, platelet and reticulocyte components. Further disclosed is a cell treatment composition for altering a nucleus property, which includes a conditioning component, a lytic component for permeating cell membrane, and a fixing component for preserving the cell nucleus. Also disclosed is a method of using the reference control for measurement of nucleated red blood cells on a blood analyzer.

The invention discloses a reticular cell detect reagent and the testing method thereof, and the reagent and the method can be applied to an apparatus based on the streaming technical principle to count accurately the analyzing reticular cell in blood specimen. The reagent and the method of the invention adopt a novel red fluorescence excitation dye which is used for marking RNA in the reticular cell, and the rapid sign of RNA in the reticular cell can be realized under the environmental temperature through a matched sphericize reagent system.

A method of measuring cellular hemoglobin of a blood sample includes mixing a blood sample with a permeation reagent, and incubating the sample mixture to permeate cellular membrane of red blood cells and to cause hemoglobin aggregation within the cells; adding a neutralization reagent to inhibit further reactions of the permeation reagent; performing a cell-by-cell measurement of side scatter signals of the red blood cells in the sample mixture on a flow cytometer; and obtaining cellular hemoglobin (Hgb_cell) of each red blood cell using the obtained side scatter signals. The method further includes measuring cellular hemoglobin of reticulocytes (Hgb_retic) by differentiating reticulocytes using a simultaneous fluorescence measurement. The method also includes measuring cellular percentage of a hemoglobin variant in mature red blood cells or reticulocytes by adding a fluorescent antibody in the neutralization reagent and detecting fluorescence signals of antibody bound hemoglobin variant.

The present invention is drawn to a hematology control made from particles a particle having a biopolymer attached to a surface of the particle. The particle simulates a component of a blood sample, such as a reticulocyte or nucleated red blood cell component of a blood cell sample in a flow cytometer or hematology analysis instrument. The present invention is further drawn to methods of making and using the hematology control.

Methods, systems, and computer program products for the analysis of a blood sample are disclosed. One embodiment is a method of detecting and enumerating hard-to-ghost cells in a blood sample. Another embodiments is a method of analyzing reticulocytes in a blood sample. Methods of using blood count parameters are also provided.

The invention discloses an application of an artemisinin derivative in preparation of medicament for treating Crohn disease, and the artemisinin derivative is selected from artesunate or artemether or styrene monomer 905 (SM905). The artemisinin derivative can be used for achieving the purpose of treating the Crohn disease by inhibiting Th1/Th17 immune response and inhibiting nuclear factor-kB activation. Compared with the existing medicaments, the artemisinin derivative has less and light side effects, in one year of following visits for the treatment of rheumatoid arthritis, transient reticulocyte decline and hepatic dysfunction only occur in individual cases, and the health can be restored by liver protection treatment without medicament withdrawal. Therefore, the artemisinin derivative can be taken by patients for a long time, the treatment can be maintained, and the purpose of effective treatment can be achieved.

A method for synthesizing dyes excitable by a helium-neon laser (excitable at 633 nm) from hololepidines, e.g., 7-halolepidine, which dyes are suitable for detection and enumeration of reticulocytes in human blood samples. In another aspect, the invention provides a method for immunotyping phenocytes. The method is based on the phenomenon that when dyes of certain structure intercalate into DNA or RNA, the intensity of the dye increases. Dyes suitable for this invention can be described as having (a) a first heterocyclic moiety, (b) a second heterocyclic moiety, and (c) a linking group that connects the first and second heterocyclic moieties. Both the first and second heterocyclic moieties must contain at least two rings, preferably fused together. The dye is characterized by conjugation, whereby the first moiety is ethylenically conjugated to the second moiety.

The invention discloses a detection chip for a tumor driving gene and application thereof. The detection chip for the tumor driving gene comprises an ALK (anaplastic lymphoma kinase) fusion detection agent, an EGFR (epidermal growth factor receptor) fusion detection agent, an RET (reticulocyte) fusion detection agent and an ROS1 (reactive oxygen species 1) fusion detection agent. Proofed by the results of clinical detect, after fusion probes corresponding to the ALK, the EGFR, the RET and the ROS1 are specifically designed, the detection chip has the advantages that the sensitivity is high, and the gene fusion between a particular site area of the ALK, the EGFR, the RET and the ROS1 and fusion segments is specifically detected. The invention further discloses a detection chip for detecting a second sequence group of the gene mutation and a third sequence group of the gene amplification; after detecting once, the gene fusion, gene mutation and gene amplification of the multiple tumor driving genes, such as the ALK, BRAF (aserine/theroninespecific kinases), DDR2 (discordin domain receptor 2), the EGFR, ERBB2 (receptor tyrosine kinase 2), FGFR1 (fibroblast growth factor receptor 1), KRAS (kirstenrat sarcoma viral oncogene), MET (methionine), NRAS, PIK3CA (phosphatidylino-sitol 3-kinases), the RET and the ROS1.

An animal blood cell measuring apparatus comprising: a specimen preparation section for preparing a measurement specimen from blood of an animal; a characteristic information obtaining section for obtaining characteristic information indicating a characteristic of the measurement specimen, from the measurement specimen prepared by the specimen preparation section; and a controller configured for performing operations comprising: (a) classifying aggregate reticulocytes contained in the blood from other blood cells, based on the characteristic information obtained by the characteristic information obtaining section; and (b) outputting information regarding a number of the classified aggregate reticulocytes.

A composition (and associated methods) including a plurality of treated red blood cells for simulating reticulocytes, and particularly an immature reticulocyte fraction, of whole blood when processed as a sample in an automated analyzer capable of detecting reticulocytes. A method for making the composition or other simulated reticulocyte may include steps of contacting a suspension of a plurality of red blood cells each having a membrane in an initial state that surrounds an interior volume of a cell with an effective amount of a hypertonic permeabilizing solution including dimethyl sulfoxide and a hypotonic loading agent delivery solution including a loading agent, for a sufficient time to form a plurality of pores in the membrane, for permitting the loading agent to enter into the interior volume of the cells.